Top ▲

Primary sclerosing cholangitis

Disease ID:784
Name:Primary sclerosing cholangitis
Associated with:1 target
1 immuno-relevant ligand
Database Links
Orphanet: ORPHA171


References:  1


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Phase 2 clinical candidate for PSC.
Clinical Use: Timolumab (with research code BTT1023) is being evaluated in Phase 2 clinical trial NCT02239211, for its potential to treat patients with primary sclerosing cholangitis, an uncommon and progressive disease of the bile ducts characterised by inflammation and obliterative fibrosis. Phase 1 studies for RA and psoriasis have been completed (2010/11). | View clinical data


Show »

1. Ellinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl JK, Shiryaev A, Gotthardt DN, Weismüller TJ et al.. (2013) Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology, 58 (3): 1074-83. [PMID:22821403]